Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870779 · ClinicalTrials.gov registry record · Phase 1
Fluorescence Guided Resection of Brain Tumors
A Phase 1 study, sponsored by David W. Roberts.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT00870779 is a Phase 1 study that has completed, run by David W. Roberts. The registered enrollment target is 105 participants.
The verdict
NCT00870779, a Phase 1 study, has completed, sponsored by David W. Roberts.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends. The surgeon usually can remove most of your tumor by looking at the MRI images that were taken of your brain before surgery. However, the surgeon does not have any good way to tell if the entire tumor has been removed or not. Removing the entire tumor is very important because leaving tumor behind may allow it to grow back which could decrease your chances of survival. It is possible to detect tumor cells by making them glow with a specific color of light (a process called fluorescence). This can be done by having you take the drug, ALA, before your surgery. ALA is a molecule that already exists in the cells of your body. Once enough of it is in your body, it gets converted into another molecule named PpIX. If blue light is shined on a tumor that has enough PpIX, it will glow with red light (fluorescence) that can be detected with a special camera. In this study, we want to determine how the fluorescence (red light) is related to the tumor which appears in the images that are normally taken of your brain (which the surgeon uses to guide the removal of your tumor) and the tumor tissue that will be removed during your surgery. Removing the entire tumor is very important because leaving tumor behind may allow it to grow back which could decrease your chances of survival.
Interventions
- DRUG 5-aminolevulinic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870779
The ClinicalTrials.gov registry entry for NCT00870779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David W. Roberts, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5-aminolevulinic acid is the first listed.
NCT00870779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00870779 about?
NCT00870779 is a clinical study titled "Fluorescence Guided Resection of Brain Tumors". Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends. The surgeon usually can remove most of your tumor by looking at the MRI images...
What is the current status of trial NCT00870779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2007-05. Estimated completion is 2013-07-02.
What interventions are being tested in trial NCT00870779?
The interventions under investigation include: 5-aminolevulinic acid (DRUG).
Who is sponsoring clinical trial NCT00870779?
This trial is sponsored by David W. Roberts, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.